Lucag . Guidotti - Infectious Diseases

Author Information

Luca Guidotti is a distinguished researcher affiliated with the Division of Immunology, Transplantation and Infectious Diseases at the IRCCS San Raffaele Scientific Institute in Milan, Italy. His work is primarily focused on the field of immunology and infectious diseases, with a particular emphasis on liver immunopathology, viral infections, and vaccine development.

Research Contributions

Dr. Guidotti has made significant contributions to the understanding of liver immunopathology and the immunobiology of hepatitis B virus (HBV) infection. His research has explored the regulation of T cell-mediated liver pathology, the effects of arenaviral infections, and the potential of low-dose aspirin in reducing HBV-associated hepatocellular carcinoma risk. Additionally, he has been involved in the development of vaccine candidates for COVID-19, demonstrating protective immune responses in animal models. His work often combines an in-depth exploration of immune mechanisms with potential therapeutic applications.

Aliases

Luca Guidotti is known by several aliases in the scientific community, including Luca G. Guidotti, L. G. Guidotti, and L G Guidotti. These variations reflect different citations and authorship listings across various publications and databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	17,216
h-index	72
Total Paper Count	139

Publications:

Group 1 ILCs regulate T cell–mediated liver immunopathology by controlling local IL-2 availability

DOI: 10.1126/sciimmunol.abi6112

Year: 2022

Arenaviral infection causes bleeding in mice due to reduced serotonin release from platelets

DOI: 10.1126/scisignal.abb0384

Year: 2022

Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: too good to be true?

DOI: 10.1002/hep.32445

Year: 2022

Developing a cure for chronic hepatitis B requires a fresh approach.

DOI: 10.1038/d41586-022-00813-0

Year: 2022

COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19

DOI: 10.1101/2021.06.14.448343

Year: 2021

Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming

DOI: 10.1016/j.immuni.2021.05.005

Year: 2021

Immunobiology and pathogenesis of hepatitis B virus infection

DOI: 10.1038/s41577-021-00549-4

Year: 2021

COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models

DOI: 10.1016/j.ymthe.2021.09.011

Year: 2021

Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion

DOI: 10.1126/sciimmunol.abl9929

Year: 2021

Controlled administration of aerosolized SARS-CoV-2 to K18-hACE2 transgenic mice uncouples respiratory infection and anosmia from fatal neuroinvasion

DOI: 10.1101/2021.08.06.455382

Year: 2021

Why are Drug Targets Important?

What is Prevalence?

What is Dengue Hemorrhagic Fever?

How Do Infectious Diseases Affect Lipid Metabolism?

What are Antimalarial Drugs?

What is Vertical Transmission?

What is the Role of Artificial Intelligence in Infectious Diseases?

Which Infectious Diseases Can Be Transmitted?

What are Pathogenic Microorganisms?

How Do Viruses Infect Host Cells?

Partnered Content Networks

Relevant Topics